Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KKaryopharm Therapeutics Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

Karyopharm Therapeutics Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Sep 1, 2026Investor Relations | Karyopharm Therapeutics
  • Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
    Aug 31, 2026Investor Relations | Karyopharm Therapeutics
  • Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
    Aug 13, 2026Investor Relations | Karyopharm Therapeutics
  • Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
    Aug 10, 2026Investor Relations | Karyopharm Therapeutics
  • Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Aug 3, 2026Investor Relations | Karyopharm Therapeutics
  • Sample Podcast #2
    Jan 6, 2021KaryoCast

    Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor...

  • Sample Podcast
    Nov 6, 2020KaryoCast

    Learn about our offerings at KaryoPharm with our latest KaryoCast!

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions